Sergliflozin etabonate

Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes[1].

Product Specifications

CAS Number

[408504-26-7]

Product Name Alternative

GW-869682X

UNSPSC

12352005

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/sergliflozin-etabonate.html

Concentration

10mM

Purity

99.64

Solubility

DMSO : ≥ 100 mg/mL

Smiles

COC(C=C1)=CC=C1CC(C=CC=C2)=C2O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)COC(OCC)=O

Molecular Formula

C23H28O9

Molecular Weight

448.46

References & Citations

[1]Katsuno K, et al. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A (y) mice. Eur J Pharmacol. 2009 Sep 15;618 (1-3) :98-104.